Genmab A/S (GMAB) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello and welcome to the GenMAP first half 2025 financial results conference call. As a reminder, this conference call is being recorded. During this telephone conference, you may be presented with forward-looking statements that include words such as beliefs, anticipates, plans, or expects. Actual results may differ materially, for example, as a result of delayed or unsuccessful development projects. GenMav is not under any obligation to update statements regarding the future, nor to confirm such statements in relation to actual results, unless this is required by law. Please also note that GenMav may hold your personal data as indicated by you as part of our investor relations outreach activities in order to update you on GenMav going forward. Please refer to our website for more information on GenMav and our privacy policy. I would now like to hand the conference over to our first speaker today, Jan van der Winkel. Please go ahead. Hello, and welcome to our financial results call for the first nine months of 2025. With me today is our Chief Financial Officer, Anthony Pagano, our Chief Commercial Officer, Brad Bailey, and our Chief Medical Officer, Taya Mahdi. And for the Q&A, we will be joined by our Chief Development Officer, Judith Klimowski. As noted, we will be making forward-looking statements, so please keep that in mind. During today's presentation, we will reference products being developed under some of our strategic collaborations, and this slide acknowledges those relationships. As we near the end of 2025, I would like to remind you of the commitments that we made at the beginning of the year. We said that we would accelerate the development of a high-impact late-stage pipeline that we would maximize the potential of our commercialized medicines, and th...